Table 1 Clinical characteristics and neuropathy parameters of participants with chronic OIPN of grade 0–1, 2, and 3 at 6 months of treatment.

From: Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy

 

Total (n = 43)

OIPN grade 0–1 (n = 13)

OIPN grade 2 (n = 25)

OIPN grade 3 (n = 5)

p-value

Age, years, mean (SD)

58.7 (9.1)

56 (12)

59 (7)

62 (7)

0.961

Sex, female, %

35

54

32

0

0.106

Colorectal cancer, %

    

0.466

Stage II/III/IV

9/75/16

0/77/23

16/72/12

0/80/20

 

Cumulative dose of oxaliplatin, mg/m2, mean (SD)

     

    At 3 months

475 (37)

465 (41)

476 (37)

492 (16)

0.356

    At 6 months

858 (129)

42 (139)

860 (125)

891 (136)

0.781

Diabetes mellitus, %

16

15

12

40

0.325

FOLFOX with bevacizumab or cetuximab, %

12

15

4

40

0.054

EORTC-CIPN20 at 3 months

24 (4)

22 (3)c

24 (4)

27 (4)c

0.042

    Sensory

11 (2)

11 (2

11 (2)

12 (2)

0.124

    Motor

9 (2)

8 (1)

9 (2)

10(1)

0.02

    Autonomic

4 (1)

3 (1)

4 (1)

5 (2)

0.058

EORTC-CIPN20 at 6 months

24 (4)

22 (3)c

24 (4)b

27 (4)bc

<0.001

    Sensory

14 (4)

12 (3)c

14 (3)b

19 (7)bc

0.002

    Motor

14 (4)

10 (3)c

10 (2)b

17 (4)b

<0.001

    Autonomic

4 (2)

4 (1)c

4 (2)

6 (2)c

0.022

a-SAP of median nerve (µV)

29 (14)

32 (17)

29 (13)

18 (4)

0.134

a-SAP of ulnar nerve (µV)

18 (9)

21 (9)

18 (9)

13 (2)

0.263

a-SAP of sural nerve (µV)

18(8)

21 (9)

18 (8)

13 (5)

0.215

SCV of median nerve (m/sec)

41 (6)

43 (5)

40 (6)

41 (6)

0.495

SCV of ulnar nerve (m/sec)

44 (4)

45 (2)

43(4)

47 (3)

0.242

SCV of sural nerve (m/sec)

38 (4)

40 (3)

37 (4)

39 (4)

0.225

NCS at 3 months

a-SAP of median nerve (µV)

24 (12)

31 (14)

22 (10)

18 (4)

0.036

a-SAP of ulnar nerve (µV)

14 (6)

18 (5)

13 (6)

11 (2)

0.042

a-SAP of sural nerve (µV)

17 (8)

21 (9)

16 (7)

12 (5)

0.057

SCV of median nerve (m/sec)

39 (5)

39 (5)

38 (6)

37 (4)

0.697

SCV of ulnar nerve (m/sec)

42 (4)

43 (3)

40 (3)

41 (4)

0.14

SCV of sural nerve (m/sec)

17 (8)

21 (9)

16 (7)

12 (5)

0.176

NCS at 6 months

a-SAP of median nerve (µV)

10 (7)

14 (8)c

9 (5)

3 (2)c

0.003

a-SAP of ulnar nerve (µV)

8 (5)

11(3)ac

8 (5)a

4(1)c

0.002

a-SAP of sural nerve (µV)

9 (4)

13 (4)ac

8 (4)a

6(3)c

0.003

SCV of median nerve (m/sec)

35(7)

37 (6)

35 (5)

28 (16)

0.067

SCV of ulnar nerve (m/sec)

36 (6)

39 (2)

35 (8)

38 (4)

0.156

SCV of sural nerve (m/sec)

33 (4)

34 (3)

32(4)

34 (3)

0.225

  1. Abbreviations: FOLFOX, infusion of fluorouracil, leucovorin, and oxaliplatin; EORTC QLQ-CIPN20, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20 module; a-SAP, amplitude of sensory nerve action potential; SCV, sensory conduction velocity.
  2. Data are mean ± SD or n (%) values. p-values <0.05 are shown in bold. ap < 0.05 between patients with OIPN grade 0–1 and grade 2, bp < 0.05 between patients with OIPN grade 2 and 3, cp < 0.05 between patients with OIPN grade 0–1 and 3.
Back to article page